- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 473/00 - Composés hétérocycliques contenant des systèmes cycliques purine
Détention brevets de la classe C07D 473/00
Brevets de cette classe: 469
Historique des publications depuis 10 ans
|
29
|
32
|
22
|
20
|
17
|
30
|
15
|
20
|
21
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Amgen Inc. | 4323 |
10 |
| Boehringer Ingelheim International GmbH | 4569 |
9 |
| Ono Pharmaceutical Co., Ltd. | 424 |
9 |
| Merck Sharp & Dohme LLC | 3726 |
9 |
| Merck Patent GmbH | 5733 |
8 |
| ChemoCentryx, Inc. | 373 |
8 |
| Gilead Sciences, Inc. | 2167 |
8 |
| Novartis AG | 10450 |
7 |
| Signal Pharmaceuticals, LLC | 177 |
7 |
| Bristol-myers Squibb Company | 4824 |
6 |
| The Regents of the University of California | 20494 |
6 |
| Forma Therapeutics, Inc. | 155 |
6 |
| Merck Sharp & Dohme Corp. | 2185 |
5 |
| Canopy Growth Corporation | 212 |
5 |
| Nerviano Medical Sciences S.r.l. | 245 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2966 |
5 |
| Takeda Pharmaceutical Company Limited | 2728 |
4 |
| Dana-Farber Cancer Institute, Inc. | 2635 |
4 |
| Saint Louis University | 293 |
4 |
| VALO Health, Inc. | 184 |
4 |
| Autres propriétaires | 340 |